# Vertical Sleeve Gastrectomy for Treatment of NASH: a pilot randomized control

> **NIH NIH R01** · UNIVERSITY OF MINNESOTA · 2022 · $309,916

## Abstract

Abstract
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that impacts 83 million Americans and is
characterized by fat (steatosis) of the liver. Twenty-five percent of individuals with NAFLD also have associated
liver cell inflammation and cell damage in a condition known as nonalcoholic steatohepatitis (NASH).
Particularly in the presence of type 2 diabetes (T2DM), NASH leads to liver fibrosis, cirrhosis, the need for liver
transplant, and an increase in mortality. There are no approved medications to treat NASH but its strong
association with obesity supports prioritization of weight loss as therapy. Lifestyle interventions (LI) that
produce weight loss, especially when close to 10% total body weight loss, can reduce the core components of
NASH and fibrosis. There are significant challenges with adherence to LI programs outside of the research
setting, highlighting the need for alternative therapies. The most common weight loss surgical procedure, the
vertical sleeve gastrectomy (VSG), reliably achieves 20% total body weight loss. The VSG not only offers
significant durable weight loss but also impacts the microbiome and metabolic regulators such as bile acids
that can influence the progression of NASH. Single-site uncontrolled studies using the liver biopsy to evaluate
NASH demonstrate improvement in both NASH and fibrosis. However, there is no level 1 evidence to
recommend the use of bariatric surgery for NASH. Controlled studies are essential as significant NASH and
fibrosis improvement have been observed in the placebo arms of pharmaceutical trials. From a definitive trial
of VSG compared to LI, we will gain important information on the safety and medium-term effect on NASH and
fibrosis improvements as well as longer term reduction in clinically meaningful events such as cirrhosis and
mortality. We will also learn who will respond to the VSG and what biomarkers might be prioritized to predict
VSG or LI outcomes to support personalized approaches for NASH therapy. At present, there is no therapy
known to improve clinical outcomes in patients with T2DM and NASH. Before a trial of this nature can be
initiated, we plan to initiate a 12 month pilot and feasibility randomized controlled trial (RCT) of VSG versus LI
for treatment of NASH in patients with prediabetes or T2DM with 3 aims to (1) Determine the relative
effectiveness of VSG on histologic improvements of the components NASH (steatosis, inflammation, cellular
damage, and fibrosis) to inform sample size calculations for a definitive trial. (2) Demonstrate that we can
recruit briskly, ensure protocol adherence, and retain participants who will undergo 12-month liver biopsies. (3)
Demonstrate that we can reliably collect and analyze potential biomarker samples, prioritizing the microbiome,
to predict and correlate with histologic outcomes. We leverage two sites with diverse populations in order to
increase generalizability of our findings. This proposal of an explanato...

## Key facts

- **NIH application ID:** 10450031
- **Project number:** 5R01DK128325-02
- **Recipient organization:** UNIVERSITY OF MINNESOTA
- **Principal Investigator:** Bilal Hameed
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $309,916
- **Award type:** 5
- **Project period:** 2021-07-14 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10450031

## Citation

> US National Institutes of Health, RePORTER application 10450031, Vertical Sleeve Gastrectomy for Treatment of NASH: a pilot randomized control (5R01DK128325-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10450031. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*